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cardiovascular (CV) disease, the leading cause of death in many
countries. The beneﬁts of lipid-lowering therapy to reduce CV-
related events are widely accepted. Clinical evidence suggests that
rosuvastatin is associated with slightly greater reductions in low-
density lipoprotein cholesterol levels than is atorvastatin at compa-
rable doses. Rosuvastatin, however, is often priced at a premium.
Objective: Our objective was to examine the cost-effectiveness of
using atorvastatin versus rosuvastatin in reducing CV events in Brazil
and Colombia using real-world prices. Methods: A global Markov
cohort model of primary and secondary CV prevention was developed
and adapted to Brazilian and Colombian settings. The risks and costs
of major CV events and efﬁcacy, adherence, and costs of statins were
considered. Total gains in life-years, quality-adjusted life-years, major
CV events avoided, and costs over the lifetime horizon were esti-
mated. Several dose comparisons were considered. Results: In the
Colombian analyses, differences in drug costs between therapies wereee front matter Copyright & 2014, International S
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A.considerable while outcomes were similar. The incremental cost per
quality-adjusted life-year gained for rosuvastatin versus atorvastatin
was more than $700,000 and $200,000 in primary and secondary
prevention, respectively. Brazilian analyses found lower incremental
cost-effectiveness ratios for rosuvastatin at some dose comparisons
due to similar pricing between statins. Sensitivity analyses revealed
that changes in treatment efﬁcacy and adherence had the largest
impact on results. Conclusions: In primary and secondary CV pre-
vention, the efﬁcacy advantage of rosuvastatin was minimal, while its
acquisition cost was higher, particularly in Colombia. The incremental
cost-effectiveness ratios were, therefore, generally in favor of atorvas-
tatin being the cost-effective option.
Keywords: atorvastatin, Brazil, cardiovascular, Colombia, cost-
effectiveness, rosuvastatin, statins.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Latin America has a high burden of cardiovascular (CV) disease.
The percentage of deaths attributable to CV disease in Latin
America and the Caribbean has been estimated at more than
30% [1,2] and in 2000 was the leading cause of death in women
aged 15 to 69 years in the region and the second leading cause
in men of the same age [1,2]. It is estimated that from 1990
to 2020, deaths from CV illness will increase by 145% in
Latin America compared with 28% to 50% in developed coun-
tries [3]. In Brazil, CV disease is responsible for 32% of total
mortality [4] and is the main cause of death in those older than
40 years [5]. There are also concerns about CV disease devel-
oping at younger ages throughout the country [6]. In Colombia,
adjusted mortality rates due to ischemic heart disease andcerebrovascular disease are roughly 1.4 to 2 times those in the
United States [7].
The increase in CV disease in Latin and South America is
thought to be due in part to major changes associated with
economic development and urbanization, the reduction in com-
municable disease, and the high prevalence of major risk factors
such as obesity and smoking [3,8–10]. For example, a survey in
Colombia found that 46% of those surveyed were overweight or
obese and 24% of women and 20% of men had high low-density
lipoprotein cholesterol (LDL-C) levels [11]. This higher burden of
CV disease and CV-related death can have substantial economic
and socioeconomic consequences, especially in countries with
limited capacity to manage disease.
The beneﬁts of lipid-lowering therapy to reduce CV events
and mortality are widely accepted [12,13]. Because of theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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their use has increased over the years [14] for both primary and
secondary prevention of CV events [15]. In Brazil, statins are
considered a ﬁrst choice for treating elevated LDL-C levels [16]
and have been shown to be effective in reducing LDL-C levels
immediately after acute myocardial infarction [17].
When multiple therapeutic choices are available, payers,
physicians, and patients must consider not only efﬁcacy and
safety but also costs. Atorvastatin and rosuvastatin are two of the
most commonly prescribed statins in much of Latin America,
each with substantial clinical support. Clinical evidence tends to
demonstrate that rosuvastatin is associated with a slightly
greater reduction in LDL-C levels than is atorvastatin at compa-
rable doses [18]. In most countries (including Brazil and Colom-
bia), rosuvastatin, however, is priced at a premium. The objective
of this analysis was to assess the cost-effectiveness of using
atorvastatin versus rosuvastatin in reducing CV events in both
primary and secondary prevention populations in Brazil and
Colombia.Methods
Cost-Effectiveness Model Overview
A global Markov cohort model was developed in Microsoft Excel
by i3 Innovus Research, Inc., to estimate the cost-effectiveness ofatorvastatin
rosuvastatin
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Fig. 1 – (A) Treatment decision tree, primary prevention, and (B
prevention models. CV, cardiovascular; CVD, cardiovascular disstatin therapies in populations at risk for CV disease. The global
model was designed to examine the effect of the use of statins on
reductions in LDL-C levels separately in primary and secondary
CV prevention. For the current analysis, the model was adapted
to the Brazilian and Colombian settings. Here, we provide a
detailed overview of the global model structure along with a
description of the adaptations made for these settings.
Model Structure
For the primary prevention model, the clinical starting point was
the decision to treat patients with atorvastatin or rosuvastatin.
Subsequent branching of the decision tree reﬂects the risk of a
major CV event (MCVE) or death (Fig. 1A). An MCVE is a composite
of myocardial infarction, stroke (ischemic or hemorrhagic), revas-
cularization (coronary artery bypass graft or percutaneous trans-
luminal coronary angioplasty), and CV-related death. The model
has three health states: 1) no previous CV event, 2) history of
MCVE, and 3) death (Fig. 1B, shown with arrows indicating
possible movements between states). Once a patient experiences
a nonfatal CV event in the primary prevention model, he or she
moves to the secondary prevention model in which he or she is at
an increased risk of death and subsequent CV events. Transitions
between health states are assumed to occur in 1-year intervals,
and the baseline transition probabilities (i.e., the risk of MCVE
and death) are based on average starting age, mean LDL-C level,
and sex of the cohort. Treatment efﬁcacy is modeled as aNo Major CV Event – see model states
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Event-speciﬁc disutility and costs are applied at the time of each
event, carried forward for the duration of the model, and
summed across all patients in each treatment arm for the
calculation of cost-effectiveness ratios. Patients are followed until
they die. The secondary prevention model is similar, except for
the possible health states, which are 1) stable CV disease (no
events have occurred during the patient’s time in the model), 2)
one nonfatal CV event, 3) two or more nonfatal CV events, and 4)
death (Fig. 1B).
Target Populations and Treatment Comparisons
The baseline risk of MCVEs and mortality for the population of
interest is deﬁned by the starting age of the cohort, the mean
LDL-C level, and the proportion of males versus females. These
reﬂect averages of the baseline characteristics from the trials in
the Cholesterol Treatment Trialists' Collaboration (CTTC) meta-
analysis [19], sorted according to primary (r3.5% annual risk of
MCVEs in the control arm) and secondary (43.5% annual risk of
MCVEs in the control arm) prevention and weighted according to
trial population size. For the reference case analysis, the primary
prevention population was deﬁned as being 33% women with a
mean age of 62 years and having a baseline LDL-C level of 137
mg/dL. For the secondary prevention population, these values
were 25% women, 64 years, and 143 mg/dL, respectively.
For the reference case analysis for primary prevention in
Colombia, atorvastatin 10 mg (A10) was compared with rosuvas-
tatin 5 mg (R5), and atorvastatin 20 mg (A20) was compared with
rosuvastatin 10 mg (R10). In the Brazilian analysis, A20 was
compared with both R10 and rosuvastatin 20 mg (R20). For
secondary prevention, the comparisons were atorvastatin 40 mg
(A40) versus R20 and atorvastatin 80 mg (A80) versus rosuvastatin
40 mg (R40) for Colombia and A40 versus R40 for Brazil.
Model Parameters and Data Sources
The risk of ﬁrst and second MCVEs (also from the CTTC meta-
analysis [19]) were calculated by using baseline trial values for
untreated patients (trials with r3.5% annual baseline risk of
MCVE per year for primary prevention, trials with 43.5% annual
baseline risk of MCVE per year for secondary prevention) and
then adjusting for the impact of each statin using the expected
statin-speciﬁc reduction in LDL-C level and the hazard ratio of a 1
mmol/L drop in the LDL-C level, which has been estimated as 0.21
[19]. After year 5, patients in each treatment arm were assumed
to have an equal risk of MCVE due to an absence of longer-term
data on reductions in LDL-C levels. Rates after the second MCVE
were extrapolated on the basis of the increase in risk between
previous MCVEs (Table 1). The distribution of MCVEs was
assumed to be 29% myocardial infarction, 19% stroke, 37%
revascularization, and 15% death [20].
For those patients experiencing an MCVE in the model, the 1-
year postevent mortality probabilities for both models were esti-
mated from the literature [21–23]. For those starting the model and
for those who survive at least 1 year after an MCVE, adjusted age-
and sex-speciﬁc all-cause mortality rates were based on national
estimates for Brazil [24] and Colombia [25]. For the Brazilian model,
the mortality inputs were calculated proportionally, considering the
informed values from the original ﬁle, assuming a proportion of
50% for each gender at the original model for both genders’
proportions. Brazilian mortality data were censored at age 80 years,
so mortality for those aged 80 to 100 years was calculated by growth
tendency from the interval from age 70 to 79 years.
Treatment efﬁcacy represents a percent reduction in LDL-C
level based on data published by Schneck et al. [18]. Speciﬁcally,
the expected percent reduction for each statin dose was as follows:A10 ¼ 38%, A20 ¼ 43%, A40 ¼ 48%, A80 ¼ 54%, R5 ¼ 42%, R10 ¼
47%, R20 ¼ 52%, and R40 ¼ 57%. Adherence was assumed to have a
proportionate impact on reductions in LDL-C levels and on costs.
The primary prevention model assumed that ﬁrst-year adherence
was 55% and in each subsequent year was 33%. For the secondary
prevention model, ﬁrst- and subsequent-year adherence was
assumed to be 70% and 48%, respectively [26]. Information about
any adherence difference for both comparators was not available.
The cost of statin therapy for the Brazilian analysis was obtained
from the Brazilian National Agency for Sanitary Vigilance maximum
price for government sales list, including taxes to the applicable
cases [27], while for the Colombian analysis, the costs represent the
institutional price reported by the Sistema de Información de
Precios de Medicamentos (National Information System Drug Price)
[28] (Table 1). To estimate the costs for MCVEs, the Colombian
analysis utilized information from a health provider with national
coverage in Colombia, and prices correspond to tariffs of 2011
adjusted to 2012 values with the Colombian consumer price index
for 2011. For the Brazilian analysis, event costs reﬂect information
available from the Brazilian Healthcare Public System Hospital data
Information System [29]; values represent the average bill for one
hospitalization event, which does not include high-cost materials
and medications nor emergency services. To adjust for emergency
services, clinical protocols [30,31] from the Brazilian Ministry of
Health were used. Procedures and examination costs were retrieved
from the SUS Management Information System of the Procedures
Medications and Materials List 2013 values [32]. Materials and
medication costs were obtained from the SUS Healthcare Prices
Database as the 2012 lowest purchase values [33] (Table 1).
Baseline utility values used to estimate the number of quality-
adjusted life-years (QALYs) associated with each treatment are
presented in Table 1. QALYs were calculated by summing the
product of utility weights associated with each health state and
the time spent in the health state. Patients who experienced
MCVEs incurred cumulative disutility based on the type and event
number (Table 1). Death was assumed to result in a utility of zero.
Cost-Effectiveness Analysis
For each reference case analysis, the number of QALYs, life-years,
MCVEs, and costs over the lifetime time horizon were summed by
the model. Incremental cost-effectiveness ratios (ICERs) were
estimated as the cost per QALY gained, cost per life-year saved,
and cost per CV event avoided. ICERs were estimated by rank-
ordering the treatment strategies by increasing cost and then
comparing the more costly strategy with the less costly strategy
by dividing the additional cost by the additional beneﬁt. A
therapy is considered to be dominated by its comparator—
referred to as simple dominance—when it is both more costly
and less effective. All costs and health outcomes were discounted
at a 3.0% annual rate for the Colombian analysis and a 5.0% rate
[34] for the Brazilian analysis, and reported in 2012 USD. When
necessary, Brazilian costs were converted to USD [35]. The
analysis was conducted from a payer perspective.
A series of deterministic sensitivity analyses (DSAs) were per-
formed by varying key model parameters through plausible ranges
while keeping other parameters constant. The parameters that
were allowed to vary within 25% of the base-case estimate included
the expected percent drop in LDL-C level, the risk reduction
associated with 1 mmol/L drop in LDL-C level, the 1-year post-CV
event mortality rates, mortality multipliers 2 or more years after an
event, adherence rates, disutility values for MCVEs, and the cost
associated with each MCVE and statin. A second-order probabilistic
sensitivity analysis (PSA) was also conducted on each reference
case scenario to assess uncertainty around selected base-case
parameter values. Using Monte-Carlo methods, the uncertainty in
these parameters was characterized by probability distributions
Table 1 – Model parameters.
Risk of MCVE %
Primary prevention
Untreated 1.83
Treated 1.41
Secondary prevention
Untreated 5.68
Untreated (patients with 2þ events) 18.01
Treated 4.48
Treated (patients with 2þ events) 14.48
Cost/unit Brazil Colombia
Statin therapy*
A10 NA 0.92
A20 1.17 1.74
A40 1.72 2.92
A80 NA 3.67
R5 NA 2.88
R10 1.18 3.43
R20 1.93 4.88
R40 2.06 6.17
Major CVE†
MI 1,523 7,441
Stroke 720 3,267
Revascularization 1,914 9.320
CV death 1,523 10,048
Utility values for both Brazil and Colombia
Baseline utility values [39] Male Female
Age 50–59 y 0.861 0.837
Age 60–69 y 0.840 0.811
Age 70–79 y 0.802 0.771
Age 80–100 y 0.782 0.724
MCVE disutility values‡ [40]
Primary prevention First event Second event Third event
MI 0.0345 0.1255 0.1185
Stroke 0.0483 0.1393 0.1323
Revascularization 0.0180 0.1090 0.1020
Secondary prevention First event Second event
MI 0.1255 0.1185
Stroke 0.1393 0.1323
Revascularization 0.1090 0.1020
Stable CVD 0.018 (applied to everyone starting model)
A10, atorvastatin 10 mg; A20, atorvastatin 20 mg; A40, atorvastatin 40 mg; A80, atorvastatin 80 mg; CV, cardiovascular; CVD, cardiovascular
disease; MCVE, major cardiovascular event; MI, myocardial infarction; NA, not applicable/available; R5, rosuvastatin 5 mg; R10, rosuvastatin 10
mg; R20, rosuvastatin 20 mg; R40, rosuvastatin 40 mg; USD, US dollars.
* 2012 USD.
† Cost per event, 2012 USD.
‡ Utility associated with death (all-cause or CV related) assumed to be equal to zero.
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standard error was assumed to be 20% of the midpoint value,
unless there were data available regarding the standard errors, in
which case those data were used. The parameters included in the
PSA were adherence rates, therapy efﬁcacy, the risk reduction for a
1 mmol/L drop in LDL-C level, mortality multipliers after a CV event
(ﬁrst year and 2 or more years after), disutility values associated
with MCVEs, and the cost of each MCVE and statin.Results
The total discounted costs for each analysis are displayed by
treatment group in Fig. 2, disaggregated by statin and MCVEtreatment costs. In both scenarios (i.e., primary and secondary
prevention) in the Colombian analysis, the drug costs for rosu-
vastatin were considerably higher than for atorvastatin and drove
the differences seen in total costs. In the Brazilian analysis, drug
costs also represented the largest portion of total costs, but in the
analysis comparing R10 with A20 (primary prevention) and R40
with A40 (secondary prevention), drug costs were similar, and as
a result, so were total costs; in the primary prevention analysis
comparing A20 with R20, the drug cost for rosuvastatin was
markedly higher, resulting in a higher total cost for the R20
cohort.
The cost-effectiveness results for the reference case analyses
are presented in Table 2. In all analyses for both countries, the
incremental differences in QALYs, life-years, and MCVE per
Fig. 2 – Discounted total cohort (n ¼ 100) costs for (A) primary and (B) secondary prevention. CVD, cardiovascular disease.
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minimal, ranging from 0 to 0.02 per patient. As a result of the
minimal clinical beneﬁts, the analyses with large differences in
drug costs produced large ICERs. In the primary prevention
analyses for Colombia, the incremental costs per QALY gained
were $700,202 (A20 vs. R10) and $811,376 (A10 vs. R5), with
incremental costs per life-year gained over $590,000 and the
cost per MCVE avoided ranging from $3.8 million to $4.4 million;
ICERs in the secondary prevention analyses were lower, ranging
from approximately $189,000 to as high as $964,000. In the
Brazilian analysis, the largest difference in drug costs was noted
in the comparison of A20 with R20 in primary prevention,
resulting in the largest ICERs. The incremental costs per QALY
gained, life-year saved, and MCVE avoided were $135,120,
$114,723, and $540,236, respectively. However, in the primary
prevention analysis comparing A20 with R10, the total drug
costs were similar, resulting in a cost per QALY gained of only
$4,335, a cost per life-year gained of $3,681, and a cost per MCVE
avoided of just above $17,000. In the Brazilian secondary
prevention model, similar drug costs also produced modest
ICERS: costs per QALY and life-year gained were both less than$20,000 while the cost per MCVE avoided was less than $40,000
(Table 2).
As demonstrated by the DSA, the variables that had the
largest impact on the results were the efﬁcacy of each therapy
in reducing the LDL-C level and the adherence rates. Fig. 3A
displays a tornado diagram for the Colombian primary preven-
tion DSA for A20 versus R10 and demonstrates that the ICERs in
these scenarios vary greatly— each treatment is dominated by
the other at some point—depending on the efﬁcacy and adher-
ence, while changes in cost and MCVE risk have a lesser effect. In
the DSA for the other Colombian primary prevention analysis
(A10 vs. R5), results were similar, except that the 1-year adher-
ence rate of rosuvastatin emerged as having the largest impact
on the cost per QALY gained (not shown). For the Brazilian
primary prevention analyses, the DSA for A20 versus R10
revealed that treatment efﬁcacy has the largest impact, yet did
not alter dominance (Fig. 3B). The DSA for A20 versus R20 was
similar, though the impact of adherence rates was much more
considerable, similar to the results shown for Colombia (Fig. 3A).
As with the Colombian models, the cost of therapy and the risk of
MCVE had less of an impact on the results. DSA results for
Table 2 – Total and incremental cost and outcomes per patient for primary and secondary prevention.
Prevention level and
treatment dose
Colombia
Total ICERs
Cost
($)
QALYs Life-
years
CV
events*
Cost/QALY
gained ($)
Cost/life-year
saved ($)
Cost/CV event
avoided ($)
Primary prevention
A10 4,438 13.41 16.81 0.30 Reference Reference Reference
R5 8,749 13.42 16.82 0.30 811,376 685,005 4,422,698
Difference 4,312 0.01 0.01 0.01 – – –
A20 6,234 13.42 16.82 0.30 Reference Reference Reference
R10 9,953 13.42 16.83 0.30 700,202 591,086 3,819,276
Difference 3,719 0.01 0.01 0.00 – – –
Secondary prevention
A40 10,633 8.63 11.12 0.80 Reference Reference Reference
R20 13,621 8.64 11.13 0.79 201,667 188,591 752,378
Difference 2,988 0.01 0.02 0.00 – – –
A80 11,748 8.65 11.14 0.79 Reference Reference Reference
R40 15,575 8.67 11.16 0.79 258,168 241,654 963,614
Difference 3,826 0.01 0.02 0.00 – – –
Brazil
Total ICERs
Cost
($)
QALYs Life-
years
CV
events*
Cost/QALY
gained ($)
Cost/life-year
saved ($)
Cost/CV event
avoided ($)
Primary prevention
A20 2,061 9.12 11.29 0.19 Reference Reference Reference
R10 2,076 9.12 11.29 0.19 4,335 3,681 17,322
Difference 15 0.00 0.00 0.00 – – –
A20 2,061 9.12 11.29 0.19 Reference Reference Reference
R20 3,223 9.13 11.30 0.19 135,120 114,723 540,236
Difference 1,162 0.01 0.01 0.01 – – –
Secondary prevention
A40 2,606 5.69 7.22 0.52 Reference Reference Reference
R40 2,957 5.72 7.24 0.51 16,771 16,620 36,783
Difference 351 0.02 0.02 0.01 – – –
A10, atorvastatin 10 mg; A20, atorvastatin 20 mg; A40, atorvastatin 40 mg; A80, atorvastatin 80 mg; CV, cardiovascular; ICER, incremental cost-
effectiveness ratio; QALY, quality-adjusted life-year; R5, rosuvastatin 5 mg; R10, rosuvastatin 10 mg; R20, rosuvastatin 20 mg; R40,
rosuvastatin 40 mg.
* Difference ¼ events avoided.
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primary prevention (not shown).
Results of the PSA for the analyses comparing A20 versus R10
in Colombia and Brazil in primary prevention are displayed in
Fig. 4. For the Colombian analysis, at a willingness-to-pay thresh-
old of $100,000 per incremental QALY, R10 had less than a 3%
chance of being the optimal therapy, and at approximately
$680,000 per QALY, this probability is 50%. The PSA curves for
A10 versus R5 in primary prevention and A40 versus R20 and A80
versus R40 in secondary prevention in Colombia had similar
proﬁles, with atorvastatin having a high probability of being the
cost-effective therapy at very low willingness-to-pay values; as
the willingness-to-pay threshold increased, the probability of
rosuvastatin becoming the cost-effective treatment improved,
reaching a probability of 50% at approximately $890,000,
$220,000, and $270,000 per QALY gained, respectively (not
shown).
In the Brazilian analyses, the PSA curves had similar proﬁles
to those of the Colombian curves; however, the thresholds at
which rosuvastatin had equal probability to atorvastatin of being
the cost-effective therapy were considerably lower; thewillingness-to-pay values to obtain an additional QALY were
approximately $13,000 (A20 vs. R10, primary prevention [Fig. 4]),
$140,000 (A20 vs. R20, primary prevention; data not shown), and
$16,000 (A40 vs. R40, secondary prevention; data not shown).Discussion
The goal of this cost-effectiveness analysis was to determine
whether the additional reduction in LDL-C level associated
with rosuvastatin translated into enough of a reduction in
major CV events to offset the additional cost compared with
equivalent doses of atorvastatin in both primary and secon-
dary prevention populations in Brazil and Colombia. The
clinical beneﬁts of rosuvastatin in each analysis were minimal,
whether measured in QALYs, life-years gained, or major CV
events avoided. This fact resulted in large ICERs when coupled
with a large differential in drug acquisition cost, and the
differences in the total costs associated with each therapy
were almost exclusively driven by the differences in costs for
the drugs themselves.
Fig. 3 – Tornado diagrams, primary prevention, for (A) Colombia A20 versus R10 and (B) Brazil A20 versus R10. A20,
atorvastatin 20 mg; CVD, cardiovascular disease; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol;
QALY, quality-adjusted life-year; R10, rosuvastatin 10 mg.
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primary prevention analyses were more than $700,000 for both
dose comparisons and for secondary prevention were more than
$200,000. The DSA demonstrated that changes in efﬁcacy and
adherence—which would, in turn, produce changes in the clinical
beneﬁt associated with each therapy—have the largest impact onthe ICERs, considering the long-term nature of the model and its
impact on direct costs for each comparator. The PSAs indicated
that willingness-to-pay thresholds of more than $600,000 per
additional QALY were necessary for rosuvastatin to have a 50%
chance of being the optimal primary prevention therapy. At the
high-dose comparisons for secondary prevention, the thresholds
Fig. 4 – CE acceptability curves, primary prevention, for (A) Colombia A20 versus R10 and (B) Brazil A20 versus R10. A20,
atorvastatin 20 mg; CE, cost-effectiveness; QALY, quality-adjusted life-year; R10, rosuvastatin 10 mg.
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tin is not a cost-effective treatment option.
For the Brazilian analysis comparing A20 with R10, total costs
were very similar, resulting in an ICER of only $4000 per QALY
gained. Although the comparison of A20 with R20 resulted in a
much larger ICER, some might not consider A20 and R20 to
represent equivalent statin doses. The ICER obtained in the
secondary prevention analysis (A40 vs. R40) was also much lower
in Brazil than in Colombia at approximately $17,000 per QALY
gained. As with the Colombian analyses, the DSAs for theBrazilian analyses indicated that changes in efﬁcacy and adher-
ence would have a large impact on the resulting ICER. As shown
in the PSAs, a willingness-to-pay threshold of only $13,000 per
QALY gained is required for R10 to have a 50% probability of being
the optimal therapy in primary prevention versus A20.
Several limitations are worth noting. First, the model used in
this analysis examines only the impact of lowering the LDL-C
level on cost-effectiveness. Also, several inputs are taken from
the CTTC meta-analysis, not directly from Latin American pop-
ulations, and therefore may not be representative of Brazilian or
V A L U E I N H E A L T H R E G I O N A L I S S U E S 5 C ( 2 0 1 4 ) 4 8 – 5 756Colombian populations. For example, previous literature has
demonstrated poor adherence to statin therapy in Brazilian
populations [36,37], often due to the cost. Because the CTTC
meta-analysis provided a hazard ratio for CV risk linked to LDL-C
level based on a large amount of clinical evidence, our model
used this new data in a novel approach to estimate cost-
effectiveness in CV prevention populations. It is well established,
however, that the risk of CV events is also affected by changes in
total cholesterol and high-density lipoprotein cholesterol levels,
among a number of other factors such as smoking status and
systolic blood pressure [38]. Given that such risk factors were not
examined in the CTTC meta-analysis, our model was limited to
considering the LDL-C level only. Finally, prices of statin therapy
as well as treatment costs for MCVE are always changing; there-
fore, these results may not apply in speciﬁc health care institu-
tions within both markets. Similar values for reduction in LDL-C
levels were reported in a previous meta-analysis according to
included statins and daily dose [41]. A recent head-to-head
comparison [42] shows that there is no statistical difference
between comparators by reducing LDL-C and LDL particles;
similar ﬁndings were reported from an open-label study [43].
Clinical beneﬁts are similar for both comparators; the difference
in acquisition costs is the critical variable for the results.
In conclusion, in most analyses, the efﬁcacy advantage of
rosuvastatin in primary and secondary CV prevention is rela-
tively small compared with the differential in acquisition cost,
especially in the analyses in the Colombian setting. The results of
our cost-effectiveness analysis suggest that the additional efﬁ-
cacy of rosuvastatin does not support its extra cost in these
scenarios. These similar results in terms of outcomes, QALYs,
life-years, and CV events suggest atorvastatin as an option that
generates lower costs to the payer than does rosuvastatin.
Source of ﬁnancial support: These ﬁndings are the result of
work supported by Pﬁzer, Inc. The views expressed in this article
are those of the authors, and no endorsement by Pﬁzer is
intended or should be inferred.
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